… Among patients aged 65 and above they found that molnupiravir reduced the risk of …
the use of molnupiravir in hospitalized patients. Wong et al. compared 1856 patients without …

… of our patients could explain it since the median age in people treated with molnupiravir
in the … Our data support the efficacy of molnupiravir also in older people without SARS-CoV-2 …

… of molnupiravir in patients … SARS-CoV-2. Improvement in pulmonary function and decline
in viral titer were noted in mice infected with SARS-CoV-2 that were administered molnupiravir […

… treatment in asymptomatic or mildly symptomatic patients can potentially prevent viral
transmissions among susceptible individuals because the prophylactic efficacy of oral …

… SARS-CoV-2 in patients with COVID-19. … of molnupiravir to reduce replication of SARS-CoV-2
and accelerate clearance of infectious virus and support ongoing trials of molnupiravir to …

… patients, reported that the early addition of molnupiravir to usual … efficacy of molnupiravir in
treating patients with COVID-19. … “coronavirus disease 2019,” “COVID-19,” “SARS coronavirus …

… from a study in patients with mild-to-moderate SARS-CoV-2 infection who received 200,
400 or 800 mg of molnupiravir twice daily for 5 days or placebo. Virus was cultured from …

… Molnupiravir has demonstrated in vitro activity against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-… Prophylactic and therapeutic administration of molnupiravir to mice …

Background Little is known about the real-world effectiveness of oral antivirals against the
SARS-CoV-2 omicron (B.1.1.529) variant. We aimed to assess the clinical effectiveness of two …

… Molnupiravir’s longitudinal impact on SARS-CoV-2 viral load from nasopharyngeal
samples was assessed through real-time polymerase chain reaction (PCR). To evaluate …